Modulation of carbonic anhydrase activity and its applications in therapy

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 5, 2004, Pages 667-702

  Scozzafava, Andrea ^a   Mastrolorenzo, Antonio ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Alzheimer's disease; Anticancer drug; Antiglaucoma agent; Antiobesity agent; Carbonic anhydrase; Enzyme activator; Enzyme inhibitor; Hypoxia; Isozyme; Metabolon; Sulfamate; Sulfamide; Sulfonamide; Tumour progression marker

Indexed keywords

ACETAZOLAMIDE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BENZENESULFONAMIDE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; BICARBONATE SODIUM COTRANSPORTER; BRIMONIDINE; BRINZOLAMIDE; CARBON DIOXIDE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE V; CELECOXIB; DICLOFENAMIDE; DORZOLAMIDE; ELIPRODIL; ETHOXZOLAMIDE; INDISULAM; LATANOPROST; METHAZOLAMIDE; PROSTAGLANDIN DERIVATIVE; ROFECOXIB; SULFAMIDE DERIVATIVE; SULFONAMIDE; SULPIRIDE; TIMOLOL MALEATE; TOPIRAMATE; UNINDEXED DRUG; VALDECOXIB; ZONISAMIDE;

ANION EXCHANGE; ANTINEOPLASTIC ACTIVITY; BITTER TASTE; CANCER; CATALYSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONJUNCTIVAL HYPEREMIA; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; EPILEPSY; EYE BURNING; GLAUCOMA; HUMAN; HYDRATION; LIPOGENESIS; MODULATION; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NONHUMAN; OBESITY; OSTEOPOROSIS; PH; PHYLOGENETIC TREE; PRURITUS; RETINA MACULA CYSTOID EDEMA; RETINOPATHY; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VISUAL IMPAIRMENT;

EID: 2542592581     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.5.667     Document Type: Review

References (138)

1. SUPURAN CT, SCOZZAFAVA A, CASINI A: Carbonic anhydrase inhibitors. Med. Res. Rev. (2003) 23:146-189.
2. SUPURAN CT, VULLO D, MANOLE G, CASINI A, SCOZZAFAVA A: Designing of novel carbonic anhydrase inhibitors and activators. Curr. Med. Chem. Cardiovasc. Hematol. Agents (2004) 2:49-68.
3. SUPURAN CT, SCOZZAFAVA A: Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin. Ther. Patents (2002) 12:217-242.
4. SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors. Curr. Med. Chem. Imm. Endoc. Metab. Agents (2001) 1:61-97.
5. SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Patents (2000) 10:575-600.
6. COX EH, MCLENDON GL, MOREL FM et al.: The active site structure of Thalassiosira weissflogii carbonic anhydrase 1. Biochemistry (2000) 39:12128-12130.
7. LANE TW, MOREL FM: A biological function for cadmium in marine diatoms. Proc. Natl. Acad. Sci. USA (2000) 97:4627-4631.
8. SO AK, ESPIE GS, WILLIAMS EB, SHIVELY JM, HEINHORST S, CANNON GC: A novel evolutionary lineage of carbonic anhydrase (epsilon class) is a component of the carboxysome shell. J. Bacteriol. (2004) 186:623-630.
9. Carbonic anhydrase - its inhibitors and activators. Supuran CT, Scozzafava A, Conway J (Eds), CRC Press, Boca Raton (FL), USA (2004):1-384 (and references cited therein).
10. PASTOREKOVA S, PARKKILA S, PASTOREK J, SUPURAN CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enz. Inhib. Med. Chem. (in press).
11. SUPURAN CT: Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther. Patents (2003) 13:1545-1550.
12. 2 hydration. J. Biol. Chem. (2000) 275:5521-5526.
13. STROP P, SMITH KS, IVERSON TM, FERRY JG, REES DC: Crystal structure of the 'cab'-type beta class carbonic anhydrase from the archaeon Methanobacterium thermoautotrophicum. J. Biol. Chem. (2001) 276:10299-10305.
14. KIMBER MS, PAI EF: The active site architecture of Pisum sativum beta-carbonic anhydrase is a mirror image of that of alpha-carbonic anhydrases. EMBO J. (2000) 19:1407-1418.
15. CRONK JD, ENDRIZZI JA, CRONK MR, O'NEILL JW, ZHANG KY: Crystal structure of E. coli β-carbonic anhydrase, an enzyme with an unusual pH-dependent activity. Protein Sci. (2001) 10:911-922.
16. IVERSON TM, ALBER BE, KISKER C, FERRY JG, REES DC: A closer look at the active site of γ-class carbonic anhydrases: high-resolution crystallographic studies of the carbonic anhydrase from Methanosarcina thermophila. Biochemistry (2000) 39:9222-9231.
17. TRIPP BC, BELL CB III, CRUZ F, KREBS C, FERRY JG: A role for iron in an ancient carbonic anhydrase. J. Biol. Chem. (2004) 279:6683-6687.
18. MERLIN C, MASTERS M, MCATEER S, COULSON A: Why is carbonic anhydrase essential to Escherichia coli? J. Bacteriol. (2003) 185:6415-6424.
19. LEHTONEN J, SHEN B, VIHINEN M et al.: Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J. Biol. Chem. (2004) 279:2719-2727.
20. WHITTINGTON DA, GRUBB JH, WAHEED A, SHAH GN, SLY WS, CHRISTIANSON DW. Expression, assay, and structure of the extracellular domain of murine carbonic anhydrase XIV: Implications for selective inhibition of membrane-associated isozymes. J. Biol. Chem. (2004) 279:7223-7228.
21. SUPURAN CT, SCOZZAFAVA A: Activation of carbonic anhydrase isozymes. In: The Carbonic Anhydrases - New Horizons, Chegwidden WR, Carter N, Edwards Y (Eds), Birkhauser Verlag, Basel, Switzerland (2000):197-219.
22. SUN MK, ALKON DL: Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats. J. Pharmacol. Exp. Ther. (2001) 297:961-967.
23. ABBATE F, CASINI A, OWA T, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. (2004) 14:217-223.
24. CASINI A, ANTEL J, ABBATE F et al.: Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. (2003) 13:841-845.
25. ABBATE F, COETZEE A, CASINI A, CIATTINI S, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg. Med. Chem. Lett. (2004) 14:337-341.
26. WEBER A, CASINI A, HEINE A et al.: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. (2004) 47:550-557.
27. FRANCHI M, VULLO D, GALLORI E et al.: Carbonic anhydrase inhibitors: inhibition of human and murine mitochondrial isozymes V with anions. Bioorg. Med. Chem. Lett. (2003) 13:2857-2861.
28. VULLO D, FRANCHI M, GALLORI E et al.: Carbonic anhydrase inhibitors. inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with anions. J. Enzyme Inhib. Med. Chem. (2003) 18:403-406.
29. SCOZZAFAVA A, SUPURAN CT: Hydroxyurea is a carbonic anhydrase inhibitor. Bioorg. Med. Chem. (2003) 11:2241-2246.
30. AGRAWAL VK, SRIVASTAVA S, KHADIKAR PV, SUPURAN CT: Quantitative structure-activity relationship study on sulfanilamide Schiff's bases: carbonic anhydrase (CA) inhibitors. Bioorg. Med. Chem. (2003) 11:5353-5562.
31. THAKUR A, THAKUR M, KHADIKAR PV, SUPURAN CT, SUDELE P: QSAR study on benzenesulphonamide carbonic anhydrase inhibitors: topological approach using Balaban index. Bioorg. Med. Chem. (2004) 12:789-793.
32. CASINI A, MINCIONE F, VULLO D, MENABUONI L, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors with strong topical antiglaucoma properties incorporating a 4-(2-aminopyrimidin-4-yl-amino)-benzenesulfonamide scaffold. J. Enzyme Inhib. Med. Chem. (2002) 17:9-18.
33. CASINI A, SCOZZAFAVA A, MINCION EF, MENABUONI L, SUPURAN CT: Carbonic anhydrase inhibitors: synthesis of water soluble sulfonamides incorporating a 4-sulfamoylphenylmethylthiourea scaffold, with potent intraocular pressure lowering properties. J. Enzyme Inhib. Med. Chem. (2002) 17:333-343.
34. CASINI A, SCOZZAFAVA A, MINCIONE F, MENABUONI L, STARNOTTI M, SUPURAN CT: Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide. Bioorg. Med. Chem. Lett. (2003) 13:2867-2873.
35. WINUM JY, CASINI A, MINCIONE F et al.: Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg. Med. Chem. Lett. (2004) 14:225-229.
36. MAESTRELLI F, MURA P, CASINI A, MINCIONE F, SCOZZAFAVA A, SUPURAN CT: Cyclodextrin complexes of sulfonamide carbonic anhydrase inhibitors as long-lasting topically acting antiglaucoma agents. J. Pharm. Sci. (2002) 91:2211-2219.
37. SCOZZAFAVA A, OWA T, MASTROLORENZO A, SUPURAN CT: Anticancer and antiviral sulfonamides. Curr. Med. Chem. (2003) 10:925-953.
38. CASINI A, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targets (2002) 2:55-75.
39. SUPURAN CT: Indisulam: an anticancer sulfonamide in clinical development. Expert Opin. Investig. Drugs (2003) 12: 283-287.
40. PASTOREKOVA S, PASTOREK J: Cancer-related carbonic anhydrase isozymes and their inhibition. In: Carbonic anhydrase - its inhibitors and activators. Supuran CT, Scozzafava A, Conway J (Eds), CRC Press, Boca Raton (FL), USA (2004):255-282.
41. VULLO D, FRANCHI M, GALLORI E et al.: Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. (2003) 13:1005-1009.
42. ILIES MA, VULLO D, PASTOREK J et al.: Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J. Med. Chem. (2003) 46:2187H2196.
43. FRANCHI M, VULLO D, GALLORI E et al.: Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides. J. Enzyme Inhib. Med. Chem. (2003) 18:333H338.
44. PASTOREKOVA S, CASINI A, SCOZZAFAVA A, VULLO D, PASTOREK J, SUPURAN CT: Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. (2004) 14:869-873.
45. WINUM JY, VULLO D, CASINI A, MONTERO JL, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J. Med. Chem. (2003) 46:2197-2204.
46. WINUM JY, VULLO D, CASINI A, MONTERO JL, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates. J. Med. Chem. (2003) 46:5471-5477.
47. PUROHIT A, WOO LW, CHANDER SK et al.: Steroid sulphatase inhibitors for breast cancer therapy. J. Steroid. Biochem. Mol. Biol. (2003) 86:423-432.
48. VULLO D, FRANCHI M, GALLORI E, ANTEL J, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J. Med. Chem. (2004) 47:1272-1279.
49. ABBATE F, SUPURAN CT, SCOZZAFAVA A, ORIOLI P, STUBBS MT, KLEBE G: Non-aromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J. Med. Chem. (2002) 45:3583-3587.
50. CASINI A, WINUM JY, MONTERO JL, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives. Bioorg. Med. Chem. Lett. (2003) 13:837-840.
51. CASINI A, ABBATE F, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a bis-sulfonamide - two heads are better than one? Bioorg. Med. Chem. Lett. (2003) 13:2759-2763.
52. ABBATE F, CASINI A, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors. J. Enzyme Inhib. Med. Chem. (2003) 18:303-308.
53. ABBATE F, CASINI A, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide. Bioorg. Med. Chem. Lett. (2004) 14:2357-2361.
54. ABBATE F, WINUM JY, POTTER BV et al.: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg. Med. Chem. Lett. (2004) 14:231-234.
55. VICKER N, HO Y, ROBINSON J et al.: Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorg. Med. Chem. Lett. (2003) 13:863-865.
56. - anion exchanger AE1. Biochemistry (2000) 39:5527-5533.
57. MCMURTRIE HL, ALVAREZ BV, LOISELLE FB et al.: The bicarbonate transport metabolon. J. Enzyme Inhib. Med. Chem. (in press).
58. STERLING D, BROWN NJ, SUPURAN CT, CASEY JR: The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II. Am. J. Physiol. Cell Physiol. (2002) 283:C1522-C1529.
59. - transport can be rescued by carbonic anhydrase II presented on an adjacent AE1 protomer. J. Biol. Chem. (2003 ) 278:44949-44958.
60. SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. Bioorg. Med. Chem. Lett. (2002) 12:1177-1180.
61. + exchanger J. Biol. Chem. (2002) 277:36085-36091.
62. - Co-transporter by carbonic anhydrase II and protein kinase Am. J. Physiol. Cell Physiol. (in press).
63. ALVAREZ BV, LOISELLE FB, SUPURAN CT, SCHWARTZ GJ, CASEY JR: Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemisty (2003) 42:12321-12329.
64. CUTHBERT AW, SUPURAN CT, MACVINISH LJ: Bicarbonate-dependent chloride secretion in Calu-3 epithelia in response to 7,8-benzoquinoline. J. Physiol. (2003) 551:79-92.
65. 2 across the human erythrocyte membrane. J. Physiol. (2003) 550:419-429.
66. FANJUL M, ALVAREZ L, SALVADOR C et al.: Evidence for a membrane carbonic anhydrase IV anchored by its C-terminal peptide in normal human pancreatic ductal cells. Histochem. Cell. Biol. (2004) 121:91-99.
67. VAUGHAN-JONES RD, SPITZER KW: Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem. Cell. Biol. (2002) 80:579-596.
68. MINCIONE F, MENABUONI L, SUPURAN CT: Clinical applications of the carbonic anhydrase inhibitors in ophthalmology. In: Carbonic anhydrase, its inhibitors and activators. Supuran CT, Scozzafava A, Conway J (Eds), CRC Press, Boca Raton (FL), USA (2004):243-254.
69. LIAO SY, IVANOV S, IVANOVA A et al.: Expression of cell surface transmembrane carbonic anhydrase genes C49 and CA12 in the human eye: overexpression of CA12 (CA XII) in glaucoma. J. Med. Genet. (2003) 40:257-261.
70. ARENDO O, HARRIS A, WOLTER P, REMKY A: Evaluation of retinal haemodynamics and retinal functions after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients. Acta. Opthalmol. Scand. (2003) 81:474-479.
71. JOSEFSSON A, SIGURDSSON SB, BANG K, EYSTEINSSON T. Dorzolamide induces vasodilatation in isolated pre-contracted bovine retinal arteries. Exp. Eye Res. (2004) 78:215-221.
72. KIILGAARD JF, PEDERSEN DB, EYSTEINSSON T et al.: Optic nerve oxygen tension: the effects of timolol and dorzolamide. Br. J. Ophthalmol. (2004) 88:276-279.
73. GIUSTI C, FORTE R, VINGOLO EM, GARGIULO P: Is acetazolamide effective in the treatment of diabetic macular edema? A pilot study. Int. Ophthalmol. (2001) 24:79-88.
74. PIKKEL J, BEIRAN I, OPHIR A, MILLER B: Acetazolamide for central serous retinopathy. Ophthalmology (2002) 109:1723-1725.
75. VILLAIN MA, PAGEAUX GP, VEYRAC M, ARNAUD B, HARRIS A, GREENFIELD DS: Effect of acetazolamide on ocular hemodynamics in pseudotumor cerebri associated with inflammatory bowel disease. Am. J. Ophthalmol. (2002) 134:778-780.
76. POTTER C, HARRIS AL: Hypoxia Inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle (2004) 3:164-167.
77. SVASTOVA E, ZILKA N, ZAT'OVICOVA M et al.: Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp. Cell Res. (2003) 290:332-345.
78. GUT MO, PARKKILA S, VERNEROVA Z et al: Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology (2002) 123:1889-1903.
79. ZAT'OVICOVA M, TARABKOVA K, SVASTOVA E et al.: Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J. Immunol. Methods (2003) 282:117-134.
80. KALUZ S, KALUZOVA M, CHRASTINA A et al.: Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1α stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res. (2002) 62:4469-4477.
81. HOSKIN PJ, SIBTAIN A, DALEY FM, WILSON GD: GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br. J. Cancer (2003) 89:1290-1297.
82. HEDLEY D, PINTILIE M, WOO J et al.: Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin. Cancer Res. (2003) 9:5666-5674.
83. BARTOSOVA M, PARKKILA S, POHLODEK K et al.: Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J. Pathol. (2002) 197:314-321.
84. TOMES L, EMBERLEY E, NIU Y et al.: Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res. Treat. (2003) 81:61-69.
85. COLPAERT CG, VERMEULEN PB, FOX SB et al.: The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res. Treat. (2003) 81:137-147.
86. JUHASZ M, CHEN J, LENDECKEL U et al.: Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment. Pharmacol. Ther. (2003) 18:837-846.
87. MANDRIOTA SJ, TURNER KJ, DAVIES DR et al.: HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell (2002) 1:459-468.
88. HUI EP, CHAN AT, PEZZELLA F et al.: Coexpression of hypoxia-inducible factors 1-α and 2-α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res. (2002) 8:2595-2604.
89. VORDERMARK D, BROWN JM: Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol. (2003) 179:801-811.
90. 125I]-labeled M75 monoclonal antibody. Neoplasma (2003) 50:13-21.
91. 125I]-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int. J. Cancer (2003) 105:873-881.
92. HERNANDEZ JM, BUI MH, HAN KR et al.: Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin. Cancer Res. (2003) 9:1906-1916.
93. LEPPILAMPI M, SAARNIO J, KARTTUNEN TJ et al.: Carbonic anhydrase isozymes IX and XII in gastric tumors. World J. Gastroenterol. (2003) 9:1398-1403.
94. ASHIDA S, NISHIMORI I, TANIMURA M, ONISHI S, SHUIN T: Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J. Cancer Res. Clin. Oncol. (2002) 128:561-568.
95. KUO WH, CHIANG WL, YANG SF et al.: The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci. (2003) 73:2211-2223.
96. LEPPILAMPI M, KOISTINEN P, SAVOLAINEN ER et al.: The expression of carbonic anhydrase II in hematological malignancies. Clin. Cancer Res. (2002) 8:2240-2245.
97. MIYAJI E, NISHIMORI I, TANIUCHI K, TAKEUCHI T, OHTSUKI Y, ONISHI S: Overexpression of carbonic anhydrase-related protein VIII in human colorectal cancer. J. Pathol. (2003) 201:37-45.
98. AKISAWA Y, NISHIMORI I, TANIUCHI K et al.: Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer. Virchows Arch. (2003) 442:66-70.
99. HEDLEY D, PINTILIE M, WOO J et al.: Upregulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. Am. J. Pathol. (2004) 164:557-565.
100. MA B, XIANG Y, LI T, YU HM, LI XJ: Inhibitory effect of TPM on Lewis lung carcinoma metastasis and its relation with AQP1 water channel. Acta Pharmacol. Sin. (2004) 25:54-60.
101. LYNCH CJ, FOX H, HAZEN SA, STANLEY BA, DODGSON SJ, LANOUE KF: Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem. J. (1995) 310:197-202.
102. SHANK RP, GARDOCKI JF, VAUGHT JL et al.: TPM: preclinical evaluation of structurally novel anticonvulsant. Epilepsia (1994) 35:450-460.
103. EDMONDS HL, JIANG YD, ZHANG PY, SHANK RP: Anticonvulsant activity of TPM and phenytoin in a rat model of ischemia-induced epilepsy. Life Sci. (1996) 59:127-131.
104. STRINGER JL: A comparison of TPM and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res. (2000) 40:147-153.
105. SABERS A, GRAM L: Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs (2000) 60:23-33.
106. BOURGEOIS BFD: Pharmacokinetics and pharmacodynamics of TPM. J. Child. Neurol. (2000) 15:S27-S30.
107. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: summary of the Fifth Eilat Conference. Epilepsy Res. (2001) 43:11-18.
108. GORDON A, PRICE LH: Mood stabilization and weight loss with TPM. Am. J. Psychiatry (1999) 156:968-969.
109. PICARD F, DESHAIES Y, LALONDE J, SAMSON P, RICHARD D: TPM reduces energy and fat gains in lean (Fal?) and obese (falfa) Zucker rats. Obesity Res. (2000) 8:656-663.
110. MASEREEL B, ROLIN S, ABBATE F, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J. Med. Chem. (2002) 45:312-320.
111. PARKKILAS, PARKKILA A-K, KIVELÄ J: Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology. In: Carbonic anhydrase - its inhibitors and activators. Supuran CT, Scozzafava A, Conway J (Eds), CRC Press, Boca Raton (FL), USA, (2004):283-302.
112. RUSSO E, CONSTANTI A: TPM hyperpolarizes and modulates the slow poststimulus AHP of rat olfactory cortical neurones in vitro. Br. J. Pharmacol. (2004) 141:285-301.
113. WAUGH J, GOA KL: TPM: as monotherapy in newly diagnosed epilepsy. CNS Drugs (2003) 17:985-992.
114. CHONG MS, LIBRETTO SE: The rationale and use of TPM for treating neuropathic pain. Clin. J. Pain (2003) 19:59-68.
115. DE CAROLIS P, MAGNIFICO F et al.: Transient hypohidrosis induced by TPM. Epilepsia (2003) 44:974-976.
116. KNUDSEN JF, THAMBI LR, KAPCALA LP, RACOOSIN JA: Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr. Neurol. (2003) 28:184-189.
117. MASTROLORENZO A, ZUCCATI G, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrases inhibitors in dermatology. In: Carbonic anhydrase - its inhibitors and activators, Supuran CT, Scozzafava A, Conway J (Eds), CRC Press, Boca Raton (FL), USA (2004):303-316.
118. BASNYAT B, GERTSCH JH, JOHNSON EW, CASTRO-MARIN F, INOUE Y, YEH C: Efficacy of low-dose acetazolamide (125 mg b.i.d.) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt. Med. Biol. (2003) 4:45-52.
119. HERSON PS, VIRK M, RUSTAY NR et al.: A mouse model of episodic ataxia type-1. Nat. Neurosci. (2003) 6:378-383.
120. SUN MK, ALKON DL: Carbonic anhydrase gating of attention: memory therapy and enhancement. Trends Pharmacol. Sci. (2002) 23:83-89.
121. CASINIA, CACCIAS, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II. Bioorg. Med. Chem. Lett. (2003) 13:2765-2768.
122. PASTERNACK M, VOIPIO J, KAILA K: Intracellular carbonic anhydrase activity and its role in GABA-induced acidosis in isolated rat hippocampal pyramidal neurones. Acta Physiol. Scand. (1993) 148:229-231.
123. SONE M, SEI H, MORITA Y, OGURA T, SONE S: The effects of acetazolamide on arterial pressure variability during REM sleep in the rat. Physiol. Behav. (1998) 63:213-218.
124. +-secreting cells of mouse and rat kidney. J. Histochem. Cytochem. (2003) 51:1217-1224.
125. PARKKILA S, KIVELA AJ, KAUNISTO K et al.: The plasma membrane carbonic anhydrase in murine hepatocytes identified as isozyme XIV. BMC Gastroenterol. (2002) 2:13-23.
126. MASTROLORENZO A, ZUCCATI G, MASSI D et al.: Immunohistochemical study of carbonic anhydrase isozymes in human skin. Eur. J. Dermatol. (2003) 13:440-444.
127. KAUNISTO K, PARKKILA S, RAJANIEMI H, WAHEED A, GRUBB J, SLY WS: Carbonic anhydrase XIV: luminal expression suggests key role in renal acidification. Kidney Int. (2002) 61:2111-2118.
128. TANIUCHI K, NISHIMORI I, TAKEUCHI T, OHTSUKI Y, ONISHI S: cDNA cloning and developmental expression of murine carbonic anhydrase-related proteins VIII, X, and XI. Brain Res. Mol. Brain Res. (2002) 109:207-215.
129. GABRIELLI MG, COX JV, MATERAZZI G, MENGHI G: Cell type-specific and developmentally regulated expression of the AE1 anion exchanger in the chicken chorioallantoic membrane. Histochem. Cell Biol. (2004) 121:189-199.
130. - cotransporters and carbonic anhydrase dependence of fluid transport in corneal endothelial cells. Am. J. Physiol. Cell Physiol. (2004) (in press).
131. HIROTA J, ANDO H, HAMADA K, MIKOSHIBA K: Carbonic anhydrase-related protein is a novel binding protein for inositol 1,4,5-trisphosphate receptor Type 1. Biochem. J. (2003) 372:435-441.
132. MALLIS RJ, HAMANN MJ, ZHAO W, ZHANG T, HENDRICH S, THOMAS JA: Irreversible thiol oxidation in carbonic anhydrase III: protection by S-glutathiolation and detection in aging rats. Biol. Chem. (2002) 383:649-662.
133. VUOTIKKA P, UUSIMAA P, NIEMELA M, VAANANEN K, VUORI J, PEUHKURINEN K: Serum myoglobin/carbonic anhydrase III ratio as a marker of reperfusion after myocardial infarction. Int. J. Cardiol. (2003) 91:137-144.
134. ENDEWARD V, KLEINKE T, GROS G: Carbonic anhydrase in the gastrointestinal mucus of mammals - possible protective role against carbon dioxide. Comp. Biochem. Physiol. A Mol. Integr. Physiol. (2003) 136:281-287.
135. KIVELA J, LAINE M, PARKKILA S, RAJANIEMI H: Salivary carbonic anhydrase VI and its relation to salivary flow rate and buffer capacity in pregnant and non-pregnant women. Arch. Oral Biol. (2003) 48:547-551.
136. WAGENAAR M, VOS PJ, HEIJDRA YF, TEPPEMA LJ, FOLGERING HT: Combined treatment with acetazolamide, and medroxyprogesterone in chronic obstructive pulmonary disease patients. Eur. Respir. J. (2002) 20:1130-1137.
137. BORTHWICK KJ, KANDEMIR N, TOPALOGLU R et al.: A phenocopy of CAII deficiency: a novel genetic explanation for inherited infantile osteopetrosis with distal renal tubular acidosis. J. Med. Genet. (2003) 40:115-121.
138. 2 capture by means of an enzyme-based reactor. Ann. NY Acad. Sci. (2003) 984:453-469.